Colossal Biosciences eyes $20‑30B valuation in new funding round
De‑extinction startup Colossal Biosciences is reportedly courting investors at a $20‑30 billion valuation, doubling its last round. The move follows the company’s first revenue streams, government contracts and spin‑outs in plastic recycling, AI modeling, and a pending artificial womb platform. Success would cement deep‑tech biotech’s appeal to mega‑cap investors.